1. Identification of new oxospiro chromane quinoline-carboxylate antimalarials that arrest parasite growth at ring stage
- Author
-
Jameel, Ehtesham, Madhav, Hari, Agrawal, Prakhar, Raza, Md. Kausar, Ahmedi, Saiema, Rahman, Abdur, Shahid, Nida, Shaheen, Kashfa, Gajra, Chhaya Haresh, Khan, Ashma, Malik, Md. Zubbair, Imam, Md. Ali, Kalamuddin, Md., Kumar, Jitendra, Gupta, Dinesh, Nayeem, Shahid M., Manzoor, Nikhat, Mohammad, Asif, Malhotra, Pawan, and Hoda, Nasimul
- Abstract
AbstractMalaria still threatens half the globe population despite successful Artemisinin-based combination therapy. One of the reasons for our inability to eradicate malaria is the emergence of resistance to current antimalarials. Thus, there is a need to develop new antimalarials targeting Plasmodiumproteins. The present study reported the design and synthesis of 4, 6 and 7-substituted quinoline-3-carboxylates 9(a–o)and carboxylic acids 10(a–b)for the inhibition of PlasmodiumN-Myristoyltransferases (NMTs) using computational biology tools followed by chemical synthesis and functional analysis. The designed compounds exhibited a glide score of −9.241 to −6.960 kcal/mol for PvNMT and −7.538 kcal/mol for PfNMT model proteins. Development of the synthesized compounds was established via NMR, HRMS and single crystal X-ray diffraction study. The synthesized compounds were evaluated for their in vitroantimalarial efficacy against CQ-sensitive Pf3D7 and CQ-resistant PfINDO lines followed by cell toxicity evaluation. In silicoresults highlighted the compound ethyl 6-methyl-4-(naphthalen-2-yloxy)quinoline-3-carboxylate (9a) as a promising inhibitor with a glide score of −9.084 kcal/mol for PvNMT and −6.975 kcal/mol for PfNMT with IC50values of 6.58 µM for Pf3D7 line. Furthermore, compounds 9nand 9oexhibited excellent anti-plasmodial activity (Pf3D7 IC50= 3.96, 6.71 µM, and PfINDO IC50= 6.38, 2.8 µM, respectively). The conformational stability of 9awith the active site of the target protein was analyzed through MD simulation and was found concordance with in vitroresults. Thus, our study provides scaffolds for the development of potent antimalarials targeting both Plasmodium vivaxand Plasmodium falciparum.Communicated by Ramaswamy H. Sarma
- Published
- 2023
- Full Text
- View/download PDF